WO2023031781 - PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS
National phase entry:
Publication Number
WO/2023/031781
Publication Date
09.03.2023
International Application No.
PCT/IB2022/058104
International Filing Date
30.08.2022
Title **
[English]
PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS
[French]
COMBINAISONS PHARMACEUTIQUES COMPRENANT UN INHIBITEUR DE TEAD ET LEURS UTILISATIONS POUR LE TRAITEMENT DE CANCERS
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
CHAPEAU, Emilie
Novartis Pharma AG
Postfach
4002 Basel, CH
L'EPICIER-SANSREGRET, Laurent
Novartis Pharma AG
Postfach
4002 Basel, CH
SCHMELZLE, Tobias
Novartis Pharma AG
Postfach
4002 Basel, CH
Priority Data
63/239,512
01.09.2021
US
63/268,481
24.02.2022
US
63/366,829
22.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4980 | |
| EPO | Filing, Examination | 17583 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 639 | |
| USA | Filing, Examination | 14010 |
Total: 37799 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to a pharmaceutical combination comprising a TEAD inhibitor in combination with a first and optionally a second therapeutically active agent. The present invention also relates to methods of treating cancer involving administering to a subject in need thereof the TEAD inhibitor in combination with the first and optionally the second therapeutically active agent.[French]
L'invention concerne une combinaison pharmaceutique comprenant un inhibiteur de TEAD en association avec un premier et éventuellement un second agent thérapeutiquement actif. La présente invention concerne également des méthodes de traitement du cancer consistant à administrer à un sujet qui en a besoin l'inhibiteur de TEAD en association avec le premier et éventuellement le second agent thérapeutiquement actif.